• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Infection . Comparison of a novel antigen detection test with reverse transcription polymerase chain reaction assay for laboratory diagnosis of SAR

tetano

Editor, Senior Moderator
Infection


. 2022 May 5.
doi: 10.1007/s15010-022-01832-9. Online ahead of print.
Comparison of a novel antigen detection test with reverse transcription polymerase chain reaction assay for laboratory diagnosis of SARS-CoV-2 infection


Osman Sezer Cirit[SUP] 1 [/SUP], Esvet Mutlu[SUP] 2 [/SUP], Banu Sancak[SUP] 3 [/SUP], Tanil Kocagöz[SUP] 4 [/SUP], Özge Can[SUP] 5 [/SUP], Candan Çicek[SUP] 6 [/SUP], Ayca Arzu Sayiner[SUP] 7 [/SUP], Özgür Appak[SUP] 7 [/SUP], Neval Yurttutan Uyar[SUP] 8 [/SUP], Canan Külah[SUP] 9 [/SUP], Aysegül Çopur Çiçek[SUP] 10 [/SUP], Osman Birol Özgümüs[SUP] 10 [/SUP], Yasemin Ay Altintop[SUP] 11 [/SUP], Esma Saatçi[SUP] 11 [/SUP], Tekin Karsligil[SUP] 12 [/SUP], Yasemin Zer[SUP] 12 [/SUP], Nevgün Sepin Özen[SUP] 13 [/SUP], Yesim Çekin[SUP] 13 [/SUP], Zeynep Ceren Karahan[SUP] 14 [/SUP], Ebru Evren[SUP] 14 [/SUP], Ayse Esra Karakoç[SUP] 15 [/SUP], Sultan Gülbahçe Orhan[SUP] 15 [/SUP], Derya Mutlu[SUP] 3 [/SUP], Tugba Bozdemir[SUP] 3 [/SUP], Yeliz Tanriverdi Çayci[SUP] 16 [/SUP], Canberk Çinar[SUP] 16 [/SUP], Meltem Tasbakan[SUP] 17 [/SUP], Merve Mert[SUP] 17 [/SUP], Ece Çinar[SUP] 18 [/SUP], Oya Özlem Eren Kutsoylu[SUP] 19 [/SUP], Sesin Kocagöz[SUP] 20 [/SUP], Ayse Ertürk[SUP] 21 [/SUP], Ilhami Çelik[SUP] 22 [/SUP], Ayse Özlem Mete[SUP] 23 [/SUP], Müge Günalp Eneyli[SUP] 24 [/SUP], Irem Akdemir[SUP] 25 [/SUP], Taliha Karakök[SUP] 26 [/SUP], Dilara Inan[SUP] 27 [/SUP], Aynur Atilla[SUP] 28 [/SUP], Şevket Onur Taflan[SUP] 29 [/SUP], Kağan Etka Yörük[SUP] 29 [/SUP]



Affiliations

Abstract

Molecular diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time reverse transcription polymerase chain reaction (RT-PCR) in respiratory specimens is considered the gold standard method. This method is highly sensitive and specific but it has some limitations such as being expensive and requiring special laboratory equipment and skilled personnel. RapidFor™ Antigen Rapid Test Kit is a commercially available Ag-RDT which is produced in Turkey and designed to detect the nucleocapsid antigen of SARS-CoV-2 in nasopharyngeal swab samples. The aim of this study was to evaluate the performance of this novel SARS-CoV-2 antigen detection considering the RT-PCR method as the gold standard. Four hundred forty-four nasopharyngeal swab samples which were collected from the patients who met clinical criteria of COVID-19 from ten centers in Turkey between September 2020 and February 2021 were included in the study. All the nasopharyngeal swab samples were tested for SARS-CoV-2 RNA using commercial RT-PCR kits (Bioeksen and A1 Lifesciences, İstanbul, Turkey) according to the manufacturer's instructions. Viral loads were assessed according to the cycle threshold (Ct) values. RapidFor™ SARS-CoV-2 antigen test (Vitrosens Biotechnology, Istanbul, Turkey) was used to investigate the presence of SARS-CoV-2 antigen in all samples following the manufacturer's instructions. Out of 444 nasopharyngeal swab samples tested, 346 (77.9%) were positive and 98 (22.1%) were negative for SARS-CoV-2 RNA by RTPCR. Overall sensitivity of the RapidFor™. Antigen Rapid Test Kit was 80.3% whereas specificity was found to be 87.8%. Positivity rate of rapid antigen test in samples with Ct values over 25 and below 30 was 82.7%, while it increased to 95.7% in samples 20 ≤ Ct < 25 and reached 100% in samples with Ct values below 20. RapidFor™ SARS-CoV-2 Ag test might be a good choice in the screening of symptomatic and asymptomatic patients and their contacts for taking isolation measures early, with advantages over RT-PCR as being rapid, easy and being applicable in every laboratory and even at point of care.

Keywords: COVID-19; Nasopharyngeal swab samples; RT-PCR; Rapid antigen test; SARS-CoV-2.
 
Back
Top Bottom